Glezen, W. P., Taber, L. H., Frank, A. L. & Kasel, J. A. Risk of Primary Infection and Reinfection With Respiratory Syncytial Virus. Am. J. Dis. Child 140, 543–546 (1986).
Google Scholar
Laufer, D. A. & Edelson, P. J. Respiratory syncytial virus infection and cardiopulmonary disease. Pediatr. Ann. 16, 644–655 (1987).
Google Scholar
Borchers, A. T., Chang, C., Gershwin, M. E. & Gershwin, L. J. Respiratory syncytial virus – A comprehensive review. Clin. Rev. Allergy Immunol. 45, 331–379 (2013).
Google Scholar
Shi, T. et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet 390, 946–958 (2017).
Google Scholar
Sigurs, N. et al. Asthma and allergy patterns over 18 years after severe RSV bronchiolitis in the first year of life. Thorax 65, 1045–1052 (2010).
Google Scholar
Stein, R. T. et al. Respiratory syncytial virus hospitalization and mortality: Systematic review and meta-analysis. Pediatric Pulmonol. 52, 556–569 (2017).
Graham, B. S. Vaccines against respiratory syncytial virus: The time has finally come. Vaccin 34, 3535–3541 (2016).
Google Scholar
Falsey, A. R., Hennessey, P. A., Formica, M. A., Cox, C. & Walsh, E. E. Respiratory Syncytial Virus Infection in Elderly and High-Risk Adults. N. Engl. J. Med. 352, 1749–1759 (2005).
Google Scholar
Elliot, A. J. & Fleming, D. M. Influenza and respiratory syncytial virus in the elderly. Expert Rev. Vaccines 7, 249–258 (2008).
Google Scholar
Hall, C. B., Walsh, E. E., Long, C. E. & Schnabel, K. C. Immunity to and frequency of reinfection with respiratory syncytial virus. J. Infect. Dis. 163, 693–698 (1991).
Google Scholar
Singleton, R., Etchart, N., Hou, S. & Hyland, L. Inability To Evoke a Long-Lasting Protective Immune Response to Respiratory Syncytial Virus Infection in Mice Correlates with Ineffective Nasal Antibody Responses. J. Virol. 77, 11303–11311 (2003).
Google Scholar
Johnson, S. et al. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J. Infect. Dis. 176, 1215–1224 (1997).
Google Scholar
Soto, J. A. et al. Current Insights in the Development of Efficacious Vaccines Against RSV. Front. Immunol. 11, 1–5 (2020).
Google Scholar
Connor, E. M. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in hieh-risk infants. the IMpact-RSV study group. Radiology 210, 295–296 (1999).
Hammitt, L. L. et al. Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants. N. Engl. J. Med. 386, 837–846 (2022).
Google Scholar
Zhu, Q. et al. A highly potent extended half-life antibody as a potential rsv vaccine surrogate for all infants. Sci. Transl. Med. 9, 1–12 (2017).
Google Scholar
Domachowske, J. B. et al. Safety, Tolerability and Pharmacokinetics of MEDI8897, an Extended Half-life Single-dose Respiratory Syncytial Virus Prefusion F-targeting Monoclonal Antibody Administered as a Single Dose to Healthy Preterm Infants. Pediatr. Infect. Dis. J. 37, 886–892 (2018).
Google Scholar
Muller, W. J. et al. Nirsevimab for Prevention of RSV in Term and Late-Preterm Infants. N. Engl. J. Med. 388, 1533–1534 (2023).
Walsh, E. E. et al. Efficacy and Safety of a Bivalent RSV Prefusion F Vaccine in Older Adults. N. Engl. J. Med. 388, 1465–1477 (2023).
Google Scholar
Papi, A. et al. Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults. N. Engl. J. Med. 388, 595–608 (2023).
Google Scholar
Kampmann, B. et al. Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants. N. Engl. J. Med. 388, 1451–1464 (2023).
Google Scholar
Fleming-Dutra, K. E. et al. Use of the Pfizer Respiratory Syncytial Virus Vaccine During Pregnancy for the Prevention of Respiratory Syncytial Virus–Associated Lower Respiratory Tract Disease in Infants: Recommendations of the Advisory Committee on Immunization Practices — United St. MMWR Morb. Mortal. Wkly Rep. 72, 920–925 (2023).
Google Scholar
Chanock, R. M., Jensen, K. & Parrott, R. H. Respiratory Syncytial Virus Disease in Infants Despite Prior Administration of Antigenic Inactivated Vaccine. Am. J. Epidemiol. 89, 422–434 (1969).
Google Scholar
Polack, F. P. et al. A role for immune complexes in enhanced respiratory syncytial virus disease. J. Exp. Med. 196, 859–865 (2002).
Google Scholar
Delgado, M. F. et al. Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nat. Med. 15, 34–41 (2009).
Google Scholar
Murphy, B. R. & Walsh, E. E. Formalin-inactivated respiratory syncytial virus vaccine induces antibodies to the fusion glycoprotein that are deficient in fusion-inhibiting activity. J. Clin. Microbiol. 26, 1595–1597 (1988).
Google Scholar
Knudson, C. J., Hartwig, S. M., Meyerholz, D. K. & Varga, S. M. RSV Vaccine-Enhanced Disease Is Orchestrated by the Combined Actions of Distinct CD4 T Cell Subsets. PLoS Pathog. 11, 1–23 (2015).
Fazolo, T. et al. Vaccination with RSV M209-223 peptide promotes a protective immune response associated with reduced pulmonary inflammation. Antivir. Res. 157, 102–110 (2018).
Google Scholar
Olson, M. R. & Varga, S. M. CD8 T Cells Inhibit Respiratory Syncytial Virus (RSV) Vaccine-Enhanced Disease. J. Immunol. 179, 5415–5424 (2007).
Google Scholar
Olson, M. R., Hartwig, S. M. & Varga, S. M. The Number of Respiratory Syncytial Virus (RSV)-Specific Memory CD8 T Cells in the Lung Is Critical for Their Ability to Inhibit RSV Vaccine-Enhanced Pulmonary Eosinophilia. J. Immunol. 181, 7958–7968 (2008).
Google Scholar
Hurwitz, J. L. Respiratory syncytial virus vaccine development. Expert Rev. Vaccines 10, 1415–1433 (2011).
Google Scholar
Lukens, M. V. et al. Characterization of the CD8+ T cell responses directed against respiratory syncytial virus during primary and secondary infection in C57BL/6 mice. Virology 352, 157–168 (2006).
Google Scholar
Srikiatkhachorn, A. & Braciale, T. J. Virus-specific CD8+ T lymphocytes downregulate T helper cell type 2 cytokine secretion and pulmonary eosinophilia during experimental murine respiratory syncytial virus infection. J. Exp. Med. 186, 421–432 (1997).
Google Scholar
Luangrath, M. A., Schmidt, M. E., Hartwig, S. M. & Varga, S. M. Tissue-Resident Memory T Cells in the Lungs Protect against Acute Respiratory Syncytial Virus Infection. ImmunoHorizons 5, 59–69 (2021).
Google Scholar
Kinnear, E. et al. Airway T cells protect against RSV infection in the absence of antibody. Mucosal Immunol. 11, 249–256 (2018).
Google Scholar
Varese, A. et al. Type I interferons and MAVS signaling are necessary for tissue resident memory CD8+ T cell responses to RSV infection. PLOS Pathog. 18, e1010272 (2022).
Google Scholar
Maier, C. et al. Mucosal immunization with an adenoviral vector vaccine confers superior protection against RSV compared to natural immunity. Front. Immunol. 13, 1–15 (2022).
Google Scholar
Lipsitch, M., Krammer, F., Regev-Yochay, G., Lustig, Y. & Balicer, R. D. SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact. Nat. Rev. Immunol. 22, 57–65 (2022).
Google Scholar
Focosi, D., Maggi, F. & Casadevall, A. Mucosal Vaccines, Sterilizing Immunity, and the Future of SARS-CoV-2 Virulence. Viruses 14, 187 (2022).
Google Scholar
Sheikh-Mohamed, S. et al. Systemic and mucosal IgA responses are variably induced in response to SARS-CoV-2 mRNA vaccination and are associated with protection against subsequent infection. Mucosal. Immunol. 15, 799–808 (2022).
Google Scholar
Lapuente, D. et al. IL-1β as mucosal vaccine adjuvant: The specific induction of tissue-resident memory T cells improves the heterosubtypic immunity against influenza A viruses article. Mucosal. Immunol. 11, 1265–1278 (2018).
Google Scholar
Lapuente, D. et al. Protective mucosal immunity against SARS-CoV-2 after heterologous systemic RNA-mucosal adenoviral vector immunization. Nat. Commun. 12, 6871 (2021).
Ambrose, C. S., Wu, X., Jones, T. & Mallory, R. M. The role of nasal IgA in children vaccinated with live attenuated influenza vaccine. Vaccine 30, 6794–6801 (2012).
Google Scholar
Morabito, K. M. et al. Intranasal administration of RSV antigen-expressing MCMV elicits robust tissue-resident effector and effector memory CD8+ T cells in the lung. Mucosal. Immunol. 10, 545–554 (2017).
Google Scholar
Morens, D. M., Taubenberger, J. K. & Fauci, A. S. Rethinking next-generation vaccines for coronaviruses, influenzaviruses, and other respiratory viruses. Cell Host Microbe 31, 146–157 (2023).
Google Scholar
Turner, D. L. et al. Lung niches for the generation and maintenance of tissue-resident memory T cells. Mucosal. Immunol. 7, 501–510 (2014).
Google Scholar
Rigter, A. et al. A Protective and Safe Intranasal RSV Vaccine Based on a Recombinant Prefusion-Like Form of the F Protein Bound to Bacterium-Like Particles. PLoS One 8, e71072 (2013).
Google Scholar
Ascough, S. et al. Local and Systemic Immunity against Respiratory Syncytial Virus Induced by a Novel Intranasal Vaccine A Randomized, Double-Blind, Placebo-controlled Clinical Trial. Am. J. Respir. Crit. Care Med. 200, 481–492 (2019).
Google Scholar
Scaggs Huang, F. et al. Safety and immunogenicity of an intranasal sendai virus-based vaccine for human parainfluenza virus type I and respiratory syncytial virus (SeVRSV) in adults. Hum. Vaccines Immunother. 17, 554–559 (2021).
Google Scholar
Lapuente, D., Ruzsics, Z., Thirion, C. & Tenbusch, M. Evaluation of adenovirus 19a as a novel vector for mucosal vaccination against influenza A viruses. Vaccine 36, 2712–2720 (2018). Available from: http://www.ncbi.nlm.nih.gov/pubmed/29628150.
Mast, T. C. et al. International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: Correlates of high Ad5 titers and implications for potential HIV vaccine trials. Vaccine 28, 950–957 (2010).
Google Scholar
Buchbinder, S. P. et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372, 1881–1893 (2008).
Google Scholar
Dudareva, M. et al. Prevalence of serum neutralizing antibodies against chimpanzee adenovirus 63 and human adenovirus 5 in Kenyan Children, in the context of vaccine vector efficacy. Vaccine 27, 3501–3504 (2009).
Google Scholar
Nidetz, N. F. et al. Adeno-associated viral vector-mediated immune responses: Understanding barriers to gene delivery. Pharm. Ther. 207, 107453 (2020).
Google Scholar
Marcandalli, J. et al. Induction of Potent Neutralizing Antibody Responses by a Designed Protein Nanoparticle Vaccine for Respiratory Syncytial Virus. Cell 176, 1420–1431.e17 (2019).
Google Scholar
Verhoeven, D., Teijaro, J. R. & Farber, D. L. Pulse-oximetry accurately predicts lung pathology and the immune response during influenza infection. Virology 390, 151–156 (2009).
Google Scholar
Afkhami, S. et al. Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2. Cell 185, 896–915.e19 (2022).
Google Scholar
Uytingco, C. R. & Martens, J. R. Intranasal delivery of adenoviral and AAV vectors for transduction of the mammalian peripheral olfactory system. Methods Mol. Biol. 1950, 283–297 (2019).
Google Scholar
Tutykhina, I. L. et al. Development of adenoviral vector-based mucosal vaccine against influenza. J. Mol. Med. 89, 331–341 (2011).
Google Scholar
Espeseth, A. S. et al. Modified mRNA/lipid nanoparticle-based vaccines expressing respiratory syncytial virus F protein variants are immunogenic and protective in rodent models of RSV infection. npj Vaccines 5, 16 (2020).
Google Scholar
Bergelson, J. M. et al. Isolation of a Common Receptor for Coxsackie B Viruses and Adenoviruses 2 and 5. Science 275, 1320–1323 (1997).
Google Scholar
Tomko, R. P., Xu, R. & Philipson, L. HCAR and MCAR: The human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc. Natl Acad. Sci. USA 94, 3352–3356 (1997).
Google Scholar
Raschperger, E. et al. The coxsackie- and adenovirus receptor (CAR) is an in vivo marker for epithelial tight junctions, with a potential role in regulating permeability and tissue homeostasis. Exp. Cell Res. 312, 1566–1580 (2006).
Google Scholar
Adams, W. C. et al. Adenovirus serotype 5 infects human dendritic cells via a coxsackievirus-adenovirus receptor-independent receptor pathway mediated by lactoferrin and DC-SIGN. J. Gen. Virol. 90, 1600–1610 (2009).
Google Scholar
Arnberg, N., Kidd, A. H., Edlund, K., Olfat, F. & Wadell, G. Initial Interactions of Subgenus D Adenoviruses with A549 Cellular Receptors: Sialic Acid versus α v Integrins. J. Virol. 74, 7691–7693 (2000).
Google Scholar
Cohen, M. et al. Influenza A penetrates host mucus by cleaving sialic acids with neuraminidase. Virol. J. 10, 1 (2013).
Google Scholar
Crespo, H. J., Lau, J. T. Y. & Videira, P. A. Dendritic cells: A spot on sialic acid. Front. Immunol. 4, 1–15 (2013).
Google Scholar
Kiener, R. et al. Vaccine vectors based on Adenovirus 19a/64 exhibit broad cellular tropism and potently restimulate HCMV-specific T cell responses ex vivo. Sci. Rep. 8, 1–13 (2018).
Google Scholar
Johnstone, R. W., Loveland, B. E. & McKenzie, I. F. C. Identification and quantification of complement regulator CD46 on normal human tissues. Immunology 79, 341–347 (1993).
Google Scholar
Verhaagh, S. et al. Human CD46-transgenic mice in studies involving replication-incompetent adenoviral type 35 vectors. J. Gen. Virol. 87, 255–265 (2006).
Google Scholar
Nimmerjahn, F. & Ravetch, J. V. Divergent Immunoglobulin G Subclass Activity through Selective Fc Receptor Binding Author (s): Falk Nimmerjahn and Jeffrey V. Ravetch. Science 310, 1510–1512 (2014).
Google Scholar
Baazim, H. et al. CD8+ T cells induce cachexia during chronic viral infection. Nat. Immunol. 20, 701–710 (2019). Available from.
Google Scholar
Schenkel, J. M. et al. Resident memory CD8 T cells trigger protective innate and adaptive immune responses. Science 346, 98–101 (2014).
Google Scholar
Schmidt, M. E. et al. Memory CD8 T cells mediate severe immunopathology following respiratory syncytial virus infection. PLoS Pathog. 14, e1006810 (2018).
Google Scholar
Rutigliano, J. A. & Graham, B. S. Prolonged Production of TNF-α Exacerbates Illness during Respiratory Syncytial Virus Infection. J. Immunol. 173, 3408–3417 (2004).
Google Scholar
Bem, R. A. et al. Activation of the granzyme pathway in children with severe respiratory syncytial virus infection. Pediatr. Res. 63, 650–655 (2008).
Google Scholar
Bem, R. A. et al. Granzyme A- and B-Cluster Deficiency Delays Acute Lung Injury in Pneumovirus-Infected Mice. J. Immunol. 184, 931–938 (2010).
Google Scholar
Hashimoto, S. et al. Upregulation of Two Death Pathways of Perforin / Granzyme and FasL / Fas in Septic. Am. J. Physiol. Lung Cell Mol. Physiol. 275, L1040–L1050 (1998).
Rosato, P. C. et al. Tissue-resident memory T cells trigger rapid exudation and local antibody accumulation. Mucosal. Immunol. 16, 17–26 (2023).
Google Scholar
Sealy, R. E., Surman, S. L., Vogel, P. & Hurwitz, J. L. Antibody-secreting cells in respiratory tract tissues in the absence of eosinophils as supportive partners. Int. Immunol. 28, 559–564 (2016).
Google Scholar
Surman, S. L., Jones, B. G., Sealy, R. E., Rudraraju, R. & Hurwitz, J. L. Oral retinyl palmitate or retinoic acid corrects mucosal IgA responses toward an intranasal influenza virus vac- cine in vitamin A deficient mice. Vaccine 32, 2521–2524 (2014).
Google Scholar
Mazanec, M. B., Coudret, C. L. & Fletcher, D. R. Intracellular neutralization of influenza virus by immunoglobulin A anti-hemagglutinin monoclonal antibodies. J. Virol. 69, 1339–1343 (1995).
Google Scholar
Murphy, B. R. et al. Effect of age and preexisting antibody on serum antibody response of infants and children to the F and G glycoproteins during respiratory syncytial virus infection. J. Clin. Microbiol. 24, 894–898 (1986).
Google Scholar
Wiegand, M. A. et al. A Respiratory Syncytial Virus Vaccine Vectored by a Stable Chimeric and Replication-Deficient Sendai Virus Protects Mice without Inducing Enhanced Disease. J. Virol. 91, e02298–16 (2017).
Google Scholar
Zohar, T. et al. Upper and lower respiratory tract correlates of protection against respiratory syncytial virus following vaccination of nonhuman primates. Cell Host Microbe 30, 41–52.e5 (2022).
Google Scholar
Shiver, J. W. & Emini, E. A. Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors. Annu. Rev. Med. 55, 355–372 (2004).
Google Scholar
Alonso-Padilla, J. et al. Development of novel adenoviral vectors to overcome challenges observed with HAdV-5-based constructs. Mol. Ther. 24, 6–16 (2016).
Google Scholar
Aoki, K. & Tagawa, Y. A twenty-one year surveillance of adenoviral conjunctivitis in Sapporo, Japan. Int Ophthalmol. Clin. 42, 49–54 (2002).
Google Scholar
Vogels, R. et al. Replication-Deficient Human Adenovirus Type 35 Vectors for Gene Transfer and Vaccination: Efficient Human Cell Infection and Bypass of Preexisting Adenovirus Immunity. J. Virol. 77, 8263–8271 (2003).
Google Scholar
Thirion, C. et al. Adenovirus vectors based on human adenovirus type 19a have high potential for human muscle-directed gene therapy. Hum. Gene Ther. 17, 193–205 (2006).
Google Scholar
Freitag, T. L. et al. Intranasal administration of adenoviral vaccines expressing SARS-CoV-2 spike protein improves vaccine immunity in mouse models. Vaccine 41, 3233–3246 (2023).
Google Scholar
Klok, F. A., Pai, M., Huisman, M. V. & Makris, M. Vaccine-induced immune thrombotic thrombocytopenia. Lancet Haematol. 9, e73–e80 (2022).
Google Scholar
Greinacher, A. et al. Pathogenesis of vaccine-induced immune thrombotic thrombocytopenia (VITT). Semin Hematol. 59, 97–107 (2022).
Google Scholar
Cines, D. B. & Greinacher, A. Vaccine-induced immune thrombotic thrombocytopenia. Blood 141, 1659–1665 (2023).
Google Scholar
McGonagle, D., De Marco, G. & Bridgewood, C. Mechanisms of Immunothrombosis in Vaccine-Induced Thrombotic Thrombocytopenia (VITT) Compared to Natural SARS-CoV-2 Infection. J. Autoimmun. 121, 102662 (2021).
Google Scholar
Stab, V. et al. Protective Efficacy and Immunogenicity of a Combinatory DNA Vaccine against Influenza A Virus and the Respiratory Syncytial Virus. PLoS One 8, e72217 (2013).
Ternette, N., Stefanou, D., Kuate, S., Uberla, K. & Grunwald, T. Expression of RNA virus proteins by RNA polymerase II dependent expression plasmids is hindered at multiple steps. Virol. J. 4, 51 (2007).
Google Scholar
Lapuente, D. et al. Innate signalling molecules as genetic adjuvants do not alter the efficacy of a DNA-based influenza A vaccine. PLoS One 15, 1–22 (2020).
Google Scholar
Hallak, L. K., Spillmann, D., Collins, P. L. & Peeples, M. E. Glycosaminoglycan Sulfation Requirements for Respiratory Syncytial Virus Infection. J. Virol. 74, 10508–10513 (2000).
Google Scholar
Vieira Antão, A. et al. Filling two needs with one deed: a combinatory mucosal vaccine against influenza A virus and respiratory syncytial virus. Front. Immunol. 15, 1–13 (2024).
Google Scholar
Anderson, K. G. et al. Cutting Edge: Intravascular Staining Redefines Lung CD8 T Cell Responses. J. Immunol. 189, 2702–2706 (2012).
Google Scholar
